But the agency should explain why different meeting types are granted than requested or denied entirely, industry representatives said during session on meeting management best practices.

Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.

Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.

The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.